Supplementary figures.docx (753.69 kB)
Supplementary figures: Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.docx
figure
posted on 2021-08-31, 10:18 authored by Stacey M. Stein, Jeremy Snider, Siraj M. Ali, Rebecca A. Miksad, Brian M. Alexander, Emily Castellanos, Alexa B. Schrock, Russell Madison, Akshay Swaminathan, Jeffrey M. Venstrom, Margaret McCusker
Supplemental
figure 1: Cohort attrition
Supplemental Figure 2: TTD and OS by IHC status for HER2 ISH+ patients with IHC results (n = 38)Supplemental figure 3: TTD and OS by KRAS status
|